breast cancer ki-67

Ki-67 is one of the important biomarkers in the diagnosis and treatment of breast cancer. The higher the positive rate of Ki-67, the more active the proliferation of tumor cells, suggesting that the tumor growth rate may be faster and the invasion may be relatively strong. This has important reference value for evaluating the malignant degree of tumor. It can help doctors to further clarify the characteristics of breast cancer, combined with other pathological indicators, to help more accurately classify breast cancer, so as to develop a more individualized treatment plan. In general, high Ki67 expression is often associated with poor prognosis, but Ki67 alone cannot be used to judge prognosis. Other factors such as tumor size and lymph node status need to be considered. For some patients with early breast cancer, Ki67 levels may affect the need for adjuvant chemotherapy and other treatment options. Changes in Ki-67 may also be used as an indicator of treatment effectiveness in neoadjuvant therapy. However, it should be noted that there are limitations in the detection and interpretation of Ki-67. Differences in detection methods and subjectivity between different observers may affect its accuracy. Therefore, in clinical practice, Ki-67 should be comprehensively analyzed with other clinicopathological indicators to provide patients with more comprehensive and accurate diagnosis and treatment recommendations.

At the same time, with the deepening of medical research, the understanding of Ki-67 in breast cancer is constantly updated and improved in order to better serve the treatment and management of patients.